Buy Rating Affirmed for Lucid Diagnostics Amid Positive Financial and Clinical Milestones
Cantor Fitzgerald Reiterates Overweight on Lucid Diagnostics, Maintains $3 Price Target
Lucid Diagnostics Analyst Ratings
Lucid Diagnostics (LUCD) Gets a Buy From Cantor Fitzgerald
Lucid Diagnostics: A Buy Rating on Operational Growth and Strategic Milestones
Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET), Jasper Therapeutics (JSPR) and Lucid Diagnostics (LUCD)
Needham Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
Lucid Diagnostics Analyst Ratings
Lucid Diagnostics: Strong Buy Rating With Significant Market Potential Despite Near-Term Losses
Needham: Reiterates Lucid Diagnostics (LUCD.US) rating and adjusted from buy to buy rating, target price is $2.50.
Lucid Diagnostics Analyst Ratings
Buy Rating Affirmed for Lucid Diagnostics Amidst Strong EsoGuard Testing Growth and Clear Reimbursement Path
Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)
Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target
Buy Rating for Lucid Diagnostics: Solid Test Volumes and Strategic Growth Initiatives Propel Market Position
Buy Rating Affirmed for Lucid Diagnostics Amid Strong Financials and Strategic Growth Initiatives
Buy Rating Affirmed for Lucid Diagnostics Amidst Growing Test Volume and Strategic Positioning for Medicare Reimbursement
Lucid Diagnostics Analyst Ratings
BTIG Sticks to Its Buy Rating for Lucid Diagnostics (LUCD)
BTIG Keeps Their Buy Rating on Lucid Diagnostics (LUCD)
No Data